Aleglitazar failed to reduce cardiovascular events in type 2 diabetes
A trial of aleglitazar to improve cardiovascular outcomes in patients with type 2 diabetes who had recent-onset acute coronary syndrome has been terminated early because of a lack of efficacy and an...